Co-Diagnostics sees 3Q net income surge as revenue rises from COVID-19 test sales

The company also said it received two important CE markings that will allow its ABC and COVID-19 2-gene tests to be sold as in-vitro diagnostics

Co-Diagnostics -
Logix Smart ABC and SARS-CoV-2 2-gene tests from Co-Diagnostics are designed for use in saliva and other respiratory tract samples

Co-Diagnostics Inc (NASDAQ:CODX) late Monday reported its third-quarter financial results, in which it generated $15.7 million in net income, or $0.53 per share, as well as year-to-date net income of $29.7 million, or  $1.07 per share.

The company also announced the receipt of CE markings for both its Logix Smart ABC and SARS-CoV-2 2-gene tests during the quarter. Both tests are designed for use in saliva and other respiratory tract samples like nasal swabs, and sputum. 

Co-Diagnostics realized revenue for the period of $21.8 million, driven by its COVID-19 test sales. CoSara Diagnostics, the company’s India joint venture, also continued its COVID-19 sales and reported $3 million of revenue, nearly a three-fold increase over 2Q.   

Co-Diagnostics CEO Dwight Egan said in a statement: “Co-Diagnostics continues to see widespread uptake of our COVID-19 test domestically and abroad, and we believe our customer and distributor bases are laying the foundation for a strong future”.

READ: Co-Diagnostics' detection of infectious disease has led it to join the coronavirus fight with flagship test

He added: “Development projects both completed and ongoing have helped position CoDiagnostics as a key player in the battle against the coronavirus pandemic, including receipt today of two important CE markings that will allow our ABC and COVID-19 2-gene tests to be sold as in vitro diagnostics in areas that accept CE markings as valid regulatory approval. The strength and flexibility of our technology platform as illustrated by our enhanced patent protection and successful proof of concept in extraction-free COVID-19 tests underscore our core competency as a forward-looking technology company with an expanding menu of critical diagnostic tools.”

Co-Diagnostics achieved gross margins of 73% on its 3Q sales and ended the period with cash and equivalents of $27.3 million as of September 30, 2020, an increase of $26.4 million from year-end 2019.

Other highlights from the quarter included the completion of design work and verification for influenza A, influenza B, and COVID-19 (ABC) multiplex panel as the company began distributing it on a Research Use Only basis to laboratories in the first week of October.

As well, Co-Diagnostics announced that its partner Clinical Reference Lab has begun selling its CRL Rapid Response COVID-19 test directly to consumers. The test uses CoPrimer probes and primers developed by Co-Diagnostics with high degrees of sensitivity and specificity.  

Contact Sean at [email protected]

Quick facts: Co-Diagnostics

Price: 11.89 USD

Market: NASDAQ
Market Cap: $336.12 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...



Full interview: Co-Diagnostic prepares test for new strain of coronavirus in...

Co-Diagnostic (NASDAQ: CODX) CEO Dwight Egan joined Proactive’s Steve Darling from New York to discuss the company being able to prepare a test for the deadly coronavirus in just 8 days. Amazing fast for such a test. Egan discussed how they were able to do that and when the test may be...

on 5/2/20

2 min read